Evidence map›Paper›PMID 38867270›Full record

ArticleLipids in health and disease2024

LDLR c.89_92dup: a novel frameshift variation in familial hypercholesterolemia.

Jialing Deng, Ju Zhang, Shirui Meng, Nan Ding, Yu Hao, Hui Zeng, Jie Lin

Abstract read
In one paragraph

Article in Lipids in health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jialing Deng *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Ju Zhang *Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Shirui MengQueen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
Nan DingBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Yu HaoBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Hui ZengBiomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. zenghui@ccmu.edu.cn.
Jie LinDepartment of Atherosclerosis, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, 100029, China. linjie1998@126.com.

Funding

National Natural Science Foundation of China 31401172National Natural Science Foundation of China 81370443the Beijing Hospital Authority DFL20191801the high-level public health talents lingjunrencai-02-06
6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia (FH) is a common inherited metabolic disease that causes premature atherosclerosis, cardiovascular disease, and even death at a young age. Approximately 95% of FH-causing genetic variants that have been identified are in the LDLR gene. However, only 10% of the FH population worldwide has been diagnosed and adequately treated, due to the existence of numerous unidentified variants, uncertainties in the pathogenicity scoring of many variants, and a substantial number of individuals lacking access to genetic testing.

objectiveThe aim of this study was to identify a novel variant in the LDLR gene that causes FH in a Chinese family, thereby expanding the spectrum of FH-causing variants.

methodsPatients were recruited from Beijing Anzhen Hospital, Capital Medical University. FH diagnosis was made according to the Dutch Lipid Clinical Network (DLCN) criteria. Whole-exome sequencing (WES) was conducted to identify the FH-causing variant in the proband, and amplicon sequencing was used to verify the variant in his family members.

resultsA three-generation Chinese family was recruited, and two FH patients were clinically diagnosed, both without known FH-causing variants. These two FH patients and another possible patient carried a novel variant, NC_000019.9(NM_000527.5):c.89_92dup (NP_000518.1:p.Phe32Argfs*21), in the ligand-binding domain of the low-density lipoprotein (LDL) receptor that led to a frameshift. The FH adults in the family showed severe clinical symptoms and statin therapy resistance.

conclusionThis study identified a novel pathogenic LDLR variant, c.89_92dup, associated with severe FH clinical manifestations and statin therapy resistance.

Indexed as

Frameshift MutationHyperlipoproteinemia Type IIPedigreeReceptors, LDLAdultExome SequencingFemaleHumansMaleMiddle AgedLDLR protein, humanReceptors, LDLc.89_92dup variantFamilial hypercholesterolemiaLigand-binding domainLow-density lipoprotein receptorWhole-exome sequencing

Identifiers

PMID38867270
PMCPMC11167941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.